Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy

被引:13
作者
Antonini, Giovanni [1 ]
Habetswallner, Francesco [2 ]
Inghilleri, Maurizio [3 ]
Mantegazza, Renato [4 ]
Rodolico, Carmelo [5 ]
Sacca, Francesco [4 ,6 ]
Sgarzi, Manlio [7 ]
deRuyck, Femke [8 ]
Paci, Sandra [8 ]
Phillips, Glenn [9 ]
Crippa, Laura [10 ]
Veronesi, Chiara [11 ]
Perrone, Valentina [11 ]
Degli Esposti, Luca [11 ]
机构
[1] Univ Roma La Sapienza, Fac Med & Psychol, Dept Neurol Mental Hlth & Sensory Organs NESMOS, Rome, Italy
[2] Cardarelli Hosp, Clin Neurophysiol Unit, Naples, Italy
[3] Sapienza Univ, Dept Human Neurosci, Neuromuscular Disorders Unit, Rome, Italy
[4] Fdn IRCCS Ist Neurol Carlo Besta, Neurol Neuroimmunol & Neuromuscular Dis Unit 4, Milan, Italy
[5] Univ Messina, Dept Clin & Expt Med, Neurol & Neuromuscular Disorders Unit, Messina, Italy
[6] Univ Naples Federico II, NSRO Dept, Naples, Italy
[7] Papa Giovanni XXIII Hosp, Dept Neurol, Bergamo, Italy
[8] Argenx BVBA, Zwijnaarde, Belgium
[9] Argenx Inc, Boston, MA USA
[10] RAReg Srl, Cesano Maderno, Italy
[11] CliCon Srl, Soc Benefit Hlth Econ & Outcomes Res, Via Murri 9, I-40137 Bologna, Italy
关键词
Myasthenia gravis; Pyridostigmine; Real word evidence; Epidemiology; Healthcare resource consumption; Administrative databases; EPIDEMIOLOGY; PROVINCE;
D O I
10.1016/j.heliyon.2023.e16367
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The purpose of this study was to investigate the epidemiology, management, and economic burden of myasthenia gravis in settings of real clinical practice. The analysis used administrative databases covering around 12 million subjects across Italy and included all adult patients with hospitalization discharge diagnosis or active exemption code for myasthenia gravis or with & GE;1 pyridostigmine prescription from 2011 to 2018. The estimated prevalence of myasthenia gravis during 2018 was in the range 13.5-29.3/100,000 people (depending on the criteria applied), corresponding to 8190-17,728 alive patients, when reproportioning data to the entire Italian population. Overall 4397 patients with myasthenia gravis (mean age 61.7 years, 46.6% males) were included. A large pyridostigmine use was observed (84.0%-46.8% from 1st to 3rd year of follow-up), followed by corticosteroids (54.5%-44.6% from 1st to 3rd year of follow-up) and nonsteroidal immunosuppressants (16% over follow-up). Total direct healthcare costs for myasthenia gravis were 4-times higher than those of the general population (euro3771 and euro869, respectively), and up to 9-fold increased when considering patients with exacerbation (euro7827). These findings showed the epidemiologic burden of myasthenia gravis and the complexity of the therapeutic management for the affected patients, with large use of treatments and elevated healthcare expenditures.
引用
收藏
页数:11
相关论文
共 33 条
[1]   Epidemiology of myasthenia gravis in northwestern Sardinia [J].
Aiello, I ;
Pastorino, N ;
Sotgiu, S ;
Pirastru, MI ;
Sau, GF ;
Sanna, G ;
Rosati, G .
NEUROEPIDEMIOLOGY, 1997, 16 (04) :199-206
[2]   Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study [J].
Andersen, J. B. ;
Owe, J. F. ;
Engeland, A. ;
Gilhus, N. E. .
EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (07) :948-955
[3]  
[Anonymous], ABOUT US
[4]  
[Anonymous], MIASTENIA VIVERE MIA
[5]   Understanding side effects of therapy for myasthenia gravis and their impact on daily life [J].
Bacci, Elizabeth Dansie ;
Coyne, Karin S. ;
Poon, Jiat-Ling ;
Harris, Linda ;
Boscoe, Audra N. .
BMC NEUROLOGY, 2019, 19 (01)
[6]  
Beloor Suresh A., 2021, MYASTHENIA GRAVIS
[7]   Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG) [J].
Berrih-Aknin, Sonia ;
Claeys, Kristl G. ;
Law, Nancy ;
Mantegazza, Renato ;
Murai, Hiroyuki ;
Sacca, Francesco ;
Dewilde, Sarah ;
Janssen, Mathieu F. ;
Bagshaw, Emma ;
Kousoulakou, Hara ;
Larkin, Mark ;
Beauchamp, Jon ;
Leighton, Trevor ;
Paci, Sandra .
BMJ OPEN, 2021, 11 (07)
[8]   An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts [J].
Boldingh, M. I. ;
Dekker, L. ;
Maniaol, A. H. ;
Brunborg, C. ;
Lipka, A. F. ;
Niks, E. H. ;
Verschuuren, J. J. G. M. ;
Tallaksen, C. M. E. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2015, 13
[9]   Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data [J].
Carey, Iain M. ;
Banchoff, Emma ;
Nirmalananthan, Niranjanan ;
Harris, Tess ;
DeWilde, Stephen ;
Chaudhry, Umar A. R. ;
Cook, Derek G. .
PLOS ONE, 2021, 16 (12)
[10]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383